UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Study suggests CD4+ T cells mediate these immune-related toxicities ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

CAR T-cell therapies achieve high response rates in relapsed/refractory MCL but have severe toxicities and complex manufacturing processes. Bispecific antibodies offer logistical advantages and ...

While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that go after a range of tumors while avoiding patients' healthy tissue. The ...